Radiosynthesis and biological evaluation of 166Ho labeled methoxylated porphyrins as possible therapeutic agents

  • Nasim Vahidfar
  • Amir R. Jalilian
  • Yousef Fazaeli
  • Ali Bahrami-Samani
  • Davood Beiki
  • Ali Khalaj


166Ho labeled 5,10,15,20-tetrakis(3,4-dimethoxyphenyl) porphyrin, and 5,10,15,20-tetrakis(3,4,5-trimethoxyphenyl) porphyrin ([166Ho]–TDMPP and [166Ho]–TTMPP respectively) were prepared with acceptable radiochemical purity and specific activities. Stability and partition coefficient of the complexes were determined in the final formulations and biodistribution studies in mouse demonstrated high accumulation of [166Ho]–TDMPP in the lung and liver and less excretion through the kidney. while [166Ho]–TTMPP was mostly excreted into intestines and kidneys while lungs were a minor accumulation site. In contrast to other reported radiolanthanide labeled porphyrins these two complexes showed less liver accumulation. Further investigation of their potential therapeutic properties is of interest.


Methoxylated porphyrins 166Ho Biodistribution Cancer therapy 



Authors wish to thank Deputy of the Research of Tehran University of Medical Sciences for the financial support of this project and also special thanks to Mr M. Mazidi for performing animal studies as well as Dr. M. Erfani and Ms. F. Bolouroinovin for performing analytical experiments.


  1. 1.
    Das T, Chakraborty S, Sarma HD, Banerjee S (2012) 109Pd labeled 5,10,15,20-tetrakis[4-carboxymethyleneoxyphenyl]porphyrin: a potential agent for targeted tumor therapy. Curr Radiopharm 5(4):340–347CrossRefGoogle Scholar
  2. 2.
    Chakraborty S, Das T, Banerjee S, Sarma HD, Venkatesh M (2007) Preparation and preliminary biological evaluation of a novel 109Pd labeled porphyrin derivative for possible use in targeted tumor therapy. Q J Nucl Med Mol Imaging 15:16–23Google Scholar
  3. 3.
    Sarma HD, Das T, Banerjee S, Venkatesh M, Vidyasagar PB, Mishra KP (2010) Biologic evaluation of a novel 188Re-labeled porphyrin in mice tumor model. Cancer Biother Radiopharm 25:47–54CrossRefGoogle Scholar
  4. 4.
    Vahidfar N, Amir R, Jalilian AR, Fazaeli Y, Bahrami-Samani A, Beiki D, Khalaj A (2013) Development and evaluation of 166holmium labelled porphyrin complex as a possible therapeutic agent. J Radioanal Nucl Chem 295(2):979–986CrossRefGoogle Scholar
  5. 5.
    Bhadwal M, Mittal S, Das T, Sarma HD, Chakraborty S, Banerjee S, Pillai MR (2013) Synthesis and biological evaluation of 177Lu–DOTA–porphyrin conjugate: a potential agent for targeted tumor radiotherapy. Q J Nucl Med Mol Imaging (Epub ahead of print)Google Scholar
  6. 6.
    Mittal S, Bhadwal M, Das T, Sarma HD, Chakravarty R, Dash A, Banerjee S, Pillai MR (2013) Synthesis and biological evaluation of 90Y-labeled porphyrin–DOTA conjugate: a potential molecule for targeted tumor therapy. Cancer Biother Radiopharm 28(9):651–656CrossRefGoogle Scholar
  7. 7.
    Ferro-Flores G, Arteaga de Murphy C, Pedraza-López M, Monroy-Guzmán F, Meléndez-Alafort L, Tendilla JI, Jiménez-Varela R (2003) Labeling of biotin with [166Dy]Dy/166Ho as a stable in vivo generator system. Int J Pharm 255:129–138CrossRefGoogle Scholar
  8. 8.
    Ferro-Flores G, Hernández-Oviedo O, Arteaga de Murphy C, Tendilla JI, Monroy-Guzmán F, Pedraza-López M, Aldama-Alvarado K (2004) [166Dy]Dy/166Ho hydroxide macroaggregates: an in vivo generator system for radiation synovectomy. Appl Radiat Isot 61:1227–1233CrossRefGoogle Scholar
  9. 9.
    Falk JE (1975) Porohyrins and metalloporphyrins. Elsevier Science Publishing, New YorkGoogle Scholar
  10. 10.
    Manual for reactor produced radioisotopes, IAEA, Vienna, 2003, IAEA-TECDOC-1340, ISBN 92-0-101103-2, ISSN 1011-4289, ©IAEA, 2003, pp.71, Printed by the IAEA in Austria, January 2003Google Scholar
  11. 11.
    Adler AD, Longo FR, Finarelli JD, Goldmacher J, Assour J, Korsakoff L (1967) A simplified synthesis for meso-tetraphenylporphine. J Org Chem 32:476CrossRefGoogle Scholar
  12. 12.
    Jalilian AR, Rowshanfarzad P, Sabet M, Novinrooz A, Raisali G (2005) Preparation of [66Ga]bleomycin complex as a possible PET Radiopharmaceutical. J Radioanal Nucl Chem 264:617–622CrossRefGoogle Scholar
  13. 13.
    Tovmasyan AG, Rajic Z, Spasojevic I, Reboucas JS, Chen X, Salvemini D, Sheng H, Warner DS, Benov L, Batinic-Haberle I (2011) Methoxy-derivatization of alkyl chains increases the in vivo efficacy of cationic Mn porphyrins. Synthesis, characterization, SOD-like activity, and SOD-deficient E. coli study of meta Mn(III) N-methoxyalkylpyridylporphyrins. Dalton Trans 40(16):4111–4121CrossRefGoogle Scholar
  14. 14.
    Fazaeli Y, Jalilian AR, Amini MM, Ardaneh K, Rahiminejad A, Bolourinovin F, Moradkhani S, Majdabadi A (2012) Development of a 68Ga-fluorinated porphyrin complex as a possible PET imaging agent. Nucl Med Mol Imaging 46:20–26CrossRefGoogle Scholar
  15. 15.
    Fazaeli Y, Jalilian AR, Amini MM, Rahiminejad A, Rajabifar S, Bolourinovin F, Moradkhani S (2011) Preparation and preliminary evaluation of [67Ga]-tetra phenyl porphyrin complexes as possible imaging agents. J Radioanal Nucl Chem 288:17–22CrossRefGoogle Scholar
  16. 16.
    Fazaeli Y, Jalilian AR, Feizi S, Shadanpour N (2013) Development of a radiothallium(III) labeld porphyrin complex as a potential imaging agent. Radiochim Acta 101:795–800CrossRefGoogle Scholar
  17. 17.
    Fazaeli Y, Jalilian AR, Amini MM, Aboudzadeh M, Feizi S, Rahiminezhad A, Yousefi K (2013) Preparation, nano purification, quality control and labelingoptimization of [64Cu]-5,10,15,20-tetrakis (penta fluoro phenyl) porphyrin complex as a possible imaging agent. J Radioanal Nucl Chem 295:255–263CrossRefGoogle Scholar
  18. 18.
    Utsumi T, Kobuchi H, Moriya K, Ogino T, Fujita H, Inoue K, Shuin T, Yasuda T, Utsumi K (2012) Mitochondrial localization of ABC transporter ABCG2 and its function in 5-aminolevulinic acid-mediated protoporphyrin IX accumulation. PLoS ONE 7(11):e50082. doi: 10.1371/journal.pone.0050082 CrossRefGoogle Scholar
  19. 19.
    Paknafas A, Fazaeli Y, Jalilian AR, Ahmadi A, Feizi S, Kamalidehghan M, Rahiminejad A, Khalaj A (2013) Radiosynthesis and quality control of [67Ga]-3,4-dimethoxylated porphyrin complex as a possible imaging agent. Iran J Pharm Res 12(4):735–744Google Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 2014

Authors and Affiliations

  • Nasim Vahidfar
    • 1
  • Amir R. Jalilian
    • 2
  • Yousef Fazaeli
    • 2
  • Ali Bahrami-Samani
    • 2
  • Davood Beiki
    • 3
  • Ali Khalaj
    • 1
  1. 1.Department of Radiopharmacy, Faculty of PharmacyTehran University of Medical SciencesTehranIran
  2. 2.Radiopharmacy Research Group, Radiation Application Research SchoolNuclear Science and Technology Research Institute (NSTRI)TehranIran
  3. 3.Research Center for Nuclear MedicineTehran University of Medical SciencesTehranIran

Personalised recommendations